NICE News August 2016

New guidance and standards Education classes essential for adults with diabetes Adults with type 1 diabetes should be offered education classes to help them manage their condition, a new quality standard from NICE says. The classes should be offered when patients are diagnosed and usually cover diet advice, weight loss for adults who are overweight, exercise and information about medicines.

Read more

News NICE approves new cancer drugs for routine NHS use Two cancer treatments, previously only available to patients through the Cancer Drugs Fund (CDF), will now be routinely available on the NHS. NICE has approved bosutinib for leukaemia and pemetrexed for lung cancer for routine use on the NHS because the companies that market them lowered their prices.

Read more

We can reduce STIs by increasing condom availability, says NICE NICE is urging local councils to increase the availability of condoms to people most at risk of sexually transmitted infections. New draft guidance, out for consultation until 16 September, recommends a different type of condom distribution scheme for each target group to help reduce STI rates.

Read more

New work from NICE could prevent thousands of people from suffering a stroke NICE is calling for GPs and clinical commissioning groups (CCGs) to focus on preventing 8,000 strokes a year. New NICE indicators will help GPs and CCGs improve the identification and management of atrial fibrillation (AF) – a common heart condition that causes an irregular heartbeat and increases the risk of stroke.

Read more

NICE recommends crizotinib for lung cancer New draft guidance from NICE means hundreds of people will now have access to crizotinib, a twice-a-day pill for lung cancer. Crizotinib is recommended for people with advanced non-small-cell lung cancer who haven't received treatment before.

Read more

Thousands to benefit as NICE set to recommend drug to prevent heart attacks and strokes NICE has published draft guidance recommending anti-clotting drug ticagrelor 60 mg with aspirin for people who have had a heart attack. In 2012/13 there were around 140,000 hospital admissions for heart attacks in England.

Read more

Draft guidance recommends new drug for people with ankylosing spondylitis New draft guidance from NICE means thousands of people with back condition ankylosing spondylitis will soon have access to an innovative new drug. The draft guidance recommends secukinumab (Cosentyx, Novartis) for treating ankylosing spondylitis, a type of arthritis that mainly affects the joints of the lower spine, leading to back pain, stiffness, swelling and tiredness.

Read more

Blogs Sugar and spice, and all things NICE Ronny Cheung, a consultant paediatrician, discusses the impact new NICE Indicators might have on type 2 diabetes.

Read more

NICE 2015-16 Annual Review microsite David Haslam, Chair of NICE, introduces this year's Annual Review microsite. Visit it to learn more about the activities we have carried out over the past year to help improve quality and productivity in health and social care.

Read more

Working together to support care at the end of life Dr Finella Craig from Great Ormond Street Hospital talks about end of life care for children.

Read more

Have your say Comment on our draft cerebral palsy guideline   This guideline covers the diagnosis, assessment and management of cerebral palsy in children and young people from birth up to their 25th birthday. Please submit your comments by 5pm on 20 September 2016.

Read more

Get involved  Join our interventional procedures advisory committee We’re looking for a nurse and a neurosurgeon or spinal surgeon to help us develop interventional procedures guidance. The closing date for applications is 5pm on Wednesday 14 September 2016.

Apply now

Time for a NICE conversation? Join us at a NICE regional stakeholder event and have your say We want to hear from you. Join us at a NICE regional stakeholder event and have your say. We want to know what you think about: how our guidance and resources are presented how they can help support the work you do Tell us how we can best meet your needs. We are holding 4 regional events to share our plans and hear what you think. If you would like to join us at any of our regional stakeholder events, please register your interest by emailing Heather.Taylor@nice.org.uk stating which event you would like to attend, along with your organisation, job title, and relevant contact details.

Read more

Attend one of our meetings in public Wed 21 September – Clinical guidelines update standing committee C (London) - Registration closes 7 September •    Intrapartum care Wed 21 September – Quality standards advisory committee 3 (Manchester) – registration closes 7 September •    Transition from children's to adults' services •    Community engagement: improving health and wellbeing Thurs 22 September – Public health advisory committee B (Manchester) – registration closes 8 September •    Flu vaccination – increasing uptake

Read more

Into Practice  Tool for putting prostate cancer guidance into practice  We have developed a tool that provides practical information and advice on our guidance on GreenLight XPS for treating benign prostatic hyperplasia. NICE's adoption and impact team worked with consultant urologists who use GreenLight XPS in NHS organisations to gather their learning and experiences.

Read more

Guidance, standards and advice      Guidance Heavy menstrual bleeding: assessment and management Autism spectrum disorder in adults: diagnosis and management Palliative care for adults: strong opioids for pain relief Fertility problems: assessment and treatment Interventional procedures guidance Extracorporeal carbon dioxide removal for acute respiratory failure Technology appraisals  Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel Bosutinib for previously treated chronic myeloid leukaemia Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer Degarelix for treating advanced hormone-dependent prostate cancer Trifluridine–tipiracil for previously treated metastatic colorectal cancer Quality standards Diabetes in adults Early years: promoting health and wellbeing in under-5s Obesity: clinical assessment and management Medtech innovation briefings Axxent electronic brachytherapy system for early stage breast cancer OSNA for colon cancer staging CORTRAK 2 Enteral Access System for placing nasoenteral feeding tubes

Free Zika virus resource portal from Wolters Kluwer

Click here to access the Zika Resource Portal

The Health division of Wolters Kluwer have launched the Zika Resource Portal, a single point of access to trusted clinical knowledge and current information to help healthcare professionals worldwide stay up-to-date on the rapidly spreading virus.

The portal provides complimentary access to leading evidence-based point-of-care clinical, learning and research solutions from Wolters Kluwer, as well as continuous updates from the Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO).

In conjunction with the portal, Wolters Kluwer is launching a multifaceted digital educational campaign featuring Zika experts sharing the latest findings in a variety of formats, including podcasts, journal articles, blogs, interactive videos and Twitter Talks.

The portal and campaign will also feature information for the public, including symptoms to look for and preventive measures to protect against contracting the virus.

The campaign centrepiece is a question and answer-style video debuting August 19 featuring Betsy Todd, RN, MPH, CIC, clinical editor of the American Journal of Nursing and an infectious disease expert. She will address the current state of the Zika virus and answer questions submitted by August 16 via Twitter and Facebook using the #WKZikaResources hashtag. Questions that are submitted using that hashtag may also be answered during an upcoming Twitter Talk.

“Wolters Kluwer is proud to provide these digital resources to help combat the spread of the Zika virus,” said Diana Nole, CEO of Wolters Kluwer Health. “The public fear and anxiety that churn in the wake of a global health crisis are often the result of the unknown. Unlike Ebola, which has been studied exhaustively for decades, Zika is still largely a mystery, although medical professionals and researchers are continuously uncovering new aspects of the virus. By sharing our expertise and premium clinical guidance, we provide the public and healthcare community with relevant, trusted on-demand information during this rapidly evolving situation.”